Semaglutide is a well-known therapy that influences appetite signaling and metabolic regulation. When prescribed appropriately, it may support patients working toward healthier body composition and improved metabolic balance.

Tirzepatide engages two important metabolic pathways — GLP-1 and GIP — and is supported by extensive clinical research. For many eligible patients, this approach may offer meaningful support when used alongside medical supervision and lifestyle strategy.